Statement: Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial.
Primary_evidence: DISEASE CHARACTERISTICS:   Histologically confirmed invasive mammary carcinoma   Stage IV disease   Basal-like disease (triple-negative, hormone-refractory, HER2-negative)   No locally recurrent breast cancer   No symptomatic brain metastases   Patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers   Patients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers   PATIENT CHARACTERISTICS:   Pre- or post-menopausal   European Cooperative Oncology Group (ECOG) performance status 0-1   Life expectancy  6 months   Absolute neutrophil count (ANC)  1,000/mm^3   Platelet count  100,000/mm^3   Creatinine  1.5 times upper limit of normal (ULN)   Total bilirubin  1.5 times ULN ( 3 times ULN in the presence of liver metastasis)   Direct bilirubin will be measured in patients with Gilbert syndrome   serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)  1.5 times ULN ( 3 times ULN in the presence of liver metastasis)   Alkaline phosphatase  3 times ULN (in the presence of liver metastasis)   Not pregnant or nursing   Negative pregnancy test   Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment   Able to swallow and retain oral medication   No malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel   No concurrent uncontrolled illness including, but not limited to, any of the following:   Ongoing or active infection requiring parenteral antibiotics   Impaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)   New York Heart Association class III-IV congestive heart failure   Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months   Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)   Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0])   Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)   Psychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary   No symptomatic neuropathy  grade 2   No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ   No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies   No history of hepatitis B or C   PRIOR CONCURRENT THERAPY:   See Disease Characteristics   Recovered from prior therapy   Prior total cumulative life-time dose of doxorubicin  360 mg/m^2 or epirubicin  640 mg/m^2   No more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)   At least 2 weeks since prior investigational drugs   At least 14 days since prior and no concurrent herbal or dietary supplements   At least 14 days since prior and no concurrent CYP3A4 inducers   At least 7 days since prior and no concurrent CYP3A4 inhibitors   Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry   No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, biologic therapy)